You are not a customer in the traditional sense
A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients
New Patient Metabolic Assessment $199 Comprehensive medical history Weight, BMI, and body measurements Progress photos Discussion of health and weight loss goals Protein goals and muscle preservation education GLP-1 education Side effect management strategies Personalized treatment plan creation Month 1 Starter Program $399 Weekly in-office visits Weekly injections Weight monitoring Side effect assessment Medication education and injection training Dose adjustments as needed Nutrition and protein guidance Ongoing support from the JCS team JCS Transform Membership $449/month Physician-supervised Tirzepatide therapy (when medically appropriate) Personalized dosing adjustments Monthly follow-up visits Weight, measurement, and body composition tracking Nutrition guidance and protein goal education Exercise recommendations Side effect and progress management Concierge access plus all JCS Transform member benefits The metabolic assessment fee is applied toward enrollment if treatment is initiated within 30 days
In a small-scale four-week long, open-label study involving 14 individuals diagnosed with major depressive disorder and bipolar disorder, which also displayed impaired executive function, treatment with liraglutide significantly reduced Hamilton Depression Rating Scale (HDRS) scores and improved executive function, however, at the same time it did not improve cognitive function in patients [122]
/assets/images/provider/photos/2805921.jpeg)
